CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Clinical trial NCT03614858 · UNKNOWN
Trial details
- NCT number
- NCT03614858
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-01
- Primary completion
- 2024-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.